Home > Products > HS-315 111-L

Calreticulin mutation antibody CAL2 - HS-315 111-L

This neoepitope is present in all NPM associated Calreticulin mutations
Mouse monoclonal purified IgG
Cat. No.: HS-315 111-L
Amount: 250 µl
Price: $650.00
Cat. No. HS-315 111-L 250 µl purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 250 µl H2O. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications
 
WB: not tested yet
Dot blot: not tested yet
ICC: not tested yet
IHC: not tested yet
IHC-P: 1 : 20 up to 1 : 40 gallery  
Clone CAL2
Subtype IgG2a (λ light chain)
Immunogen Recombinant protein corresponding to the neoepitope in human mutated calreticulin. (UniProt Id: P27797)
Reactivity Reacts with: human (P27797).
Other species not tested yet.
Specificity Specific for the neoepitope in mutated Calreticulin.
Data sheet hs-315_111-l.pdf

References for Calreticulin mutation - HS-315 111-L

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
Mózes R, Gángó A, Sulák A, Vida L, Reiniger L, Timár B, Krenács T, Alizadeh H, Masszi T, Gaál-Weisinger J, Demeter J, et al.
Pathology (2018) : . HS-315 111-L IHC-P; tested species: human
A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies.
Stein H, Bob R, Dürkop H, Erck C, Kämpfe D, Kvasnicka HM, Martens H, Roth A, Streubel A
Leukemia (2016) 301: 131-5. HS-315 111-L IHC-P; tested species: human
Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.
Andrici J, Farzin M, Clarkson A, Sioson L, Sheen A, Watson N, Toon CW, Koleth M, Stevenson W, Gill AJ
Pathology (2016) 484: 319-24. HS-315 111-L IHC-P; tested species: human
CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
Nomani L, Bodo J, Zhao X, Durkin L, Loghavi S, Hsi ED
American journal of clinical pathology (2016) 1464: 431-8. HS-315 111-L IHC-P; tested species: human
Cat. No.: HS-315 111-L
Amount: 250 µl
Price: $650.00

Detection of Calreticulin mutation in primary myelofibrosis

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
Mózes R, Gángó A, Sulák A, Vida L, Reiniger L, Timár B, Krenács T, Alizadeh H, Masszi T, Gaál-Weisinger J, Demeter J, et al.
Pathology (2018) : . HS-315 111-L IHC-P; tested species: human
A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies.
Stein H, Bob R, Dürkop H, Erck C, Kämpfe D, Kvasnicka HM, Martens H, Roth A, Streubel A
Leukemia (2016) 301: 131-5. HS-315 111-L IHC-P; tested species: human
Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.
Andrici J, Farzin M, Clarkson A, Sioson L, Sheen A, Watson N, Toon CW, Koleth M, Stevenson W, Gill AJ
Pathology (2016) 484: 319-24. HS-315 111-L IHC-P; tested species: human
CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
Nomani L, Bodo J, Zhao X, Durkin L, Loghavi S, Hsi ED
American journal of clinical pathology (2016) 1464: 431-8. HS-315 111-L IHC-P; tested species: human
IHC-P
Background

Calreticulin (CALR) mutations have been identified as a major driver in myeloproliferative neoplasms (MPNs). In contrast to JAK2 mutations that are mainly associated with polycythaemia vera (PV), CALR mutations are specifically associated with primary myelofibrosis (PMF) and essential thrombocythaemia (ET).

All known types of CALR mutations result in a novel C-terminus of the protein. This harbors a common epitope expressed in all kinds of CALR mutations. The CAL2 antibody is directed against this neoepitope. Therefore, it can be concluded that the CAL2 antibody is able to detect all CALR mutations.

It labels the megakaryocytes in myeloproliferative neoplasms (essential thrombocythaemia (ET) and primary myelofibrosis (PMF)) with CALR mutation and enables to distinguish them from polycythemia vera (PV), from CALR mutation negative ET and PMF and from reactive bone marrow.
Protocols for HS-315 111-L
IHC-P
Other products for this target